PetMeds 10-Q: Going-Concern Doubt Disclosed, Material Weaknesses Persist, $37M Sale-Leaseback Pending
PETS is trading near its 52-week low of $1.15 (3.5% above the low).
Summary
PetMeds' Q2 10-Q shows cash down to $11.4 million, negative $17.0 million working capital and a going-concern assessment management says its cost cuts alleviate, plus a still-unclosed $37.0 million sale-leaseback of its Florida headquarters.
Key Events · Earnings and Guidance · PETS
-
Going-Concern Doubt Disclosed
Management identified conditions raising substantial doubt about the ability to continue as a going concern: cash fell to $11.4 million from $21.4 million at March 31, 2026, working capital dropped to $(17.0) million from $(8.4) million, sales fell 19.4%, and operating cash flow was negative. Management concluded the doubt is alleviated by planned cuts to marketing, operating expenses and capital spending.
-
Q2 Loss Narrows on Cost Cuts
Net sales were $35.8 million versus $44.4 million a year ago, a 19.4% decline, while net loss narrowed to $6.4 million, or $0.31 per share, from $8.5 million, or $0.41. Adjusted EBITDA worsened to $(3.6) million from $(2.3) million.
-
Material Weaknesses Unremediated
The previously disclosed material weaknesses in sales taxes, IT general controls, revenue recognition and cooperative advertising/vendor reimbursements had not been fully remediated as of September 30, 2026, and management concluded disclosure controls and procedures were not effective.
-
$37.0M Sale-Leaseback Still Pending
A July 23, 2026 purchase and sale agreement covers the Delray Beach headquarters and Florida distribution center for $37.0 million, with a 10-year triple-net leaseback of 100,519 square feet. Terms are still under discussion and the properties are not classified as held for sale, so closing is not assured.
Analysis · PETS · Trade & Services
The headline numbers were already out — sales of $35.8 million, down 19.4%, and a $6.4 million net loss — but the 10-Q is where the balance-sheet stress becomes explicit. Over six months, cash fell to $11.4 million from $21.4 million while working capital went to negative $17.0 million, and management states these conditions raised substantial doubt about the ability to continue as a going concern, alleviated only by its own cost-cut plan. The company also confirms its previously disclosed material weaknesses in sales taxes, IT controls, revenue recognition and vendor reimbursements were still not remediated at September 30, 2026, so disclosure controls were not effective. The one large asset left is the Delray Beach headquarters and distribution center, under contract to sell for $37.0 million with a 10-year leaseback — but terms are still being negotiated and the properties are not classified as held for sale, so that cash is not assured. With no debt and no alternative sources of working capital, the runway depends on continued expense cuts and closing that sale.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PETS was trading at $1.19 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $26.2M. The 52-week trading range was $1.15 to $4.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.